Skip to main content
Have a personal or library account? Click to login
The cost of systemic therapy for metastatic colorectal carcinoma in Slovenia: discrepancy analysis between cost and reimbursement Cover

The cost of systemic therapy for metastatic colorectal carcinoma in Slovenia: discrepancy analysis between cost and reimbursement

Radiology and Oncology
Volume 49 (2015): Issue 2 (June 2015)
By: ,  ,  ,   and    
Open Access
|Mar 2015
References

References

  1. 1. Zakelj MP, Zadnik V, Zagar T, Zakotnik B. Survival of cancer patients, diagnosed in 1991-2005 in Slovenia. Ljubljana: Institute of Oncology Ljubljana, Epidemiology and Cancer Registry, Cancer Registry of Republic of Slovenia; 2009. p. 229.
    Search in Google Scholar
  2. 2. Treglia G, Taralli S, Salsano M, Muoio B, Sadeghi R, Giovanella L. Prevalence and malignancy risk of focal colorectal incidental uptake detected by 18F-FDG-PET or PET/CT: a meta-analysis. Radiol Oncol 2015; 49(2): 200-208.; 48: 99-104.
    Open DOISearch in Google Scholar
  3. 3. Ocvirk J. Advances in the treatment of metastatic colorectal carcinoma. Radiol Oncol 2009; 43: 1-8.
    Open DOISearch in Google Scholar
  4. 4. Ocvirk J, Heeger S, McCloud P, Hofheinz RD. A review of the treatment options for skin rash induced by EGFR-targeted therapies: Evidence from randomized clinical trials and a meta-analysis. Radiol Oncol 2013; 47: 166-75.
    Open DOISearch in Google Scholar
  5. 5. Reeder CE, Gordon D. Managing oncology costs. Am J Manag Care., 2006; 12: 3-16.
    Search in Google Scholar
  6. 6. Van Cutsem EJD, Oliveira J. On behalf of the ESMO Guidelines Working Group. Advanced colorectal cancer: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. Ann Oncol 2008; 19(Suppl 2): ii33-4.
    Open DOISearch in Google Scholar
  7. 7. Mesti T. [The cost of systemic therapy for metastatic colorectal carcinoma at Institute of Oncology Ljubljana in the year 2009]. Master’s thesis. [Slovenian]. University of Ljubljana, Faculty of Economics; 2011. Available at: http://www.cek.ef.uni-lj.si/magister/mesti4363.pdf
    Search in Google Scholar
  8. 8. Song X, Zhao Z, Barber B, Gregory C, Zhun C, Sue G. Cost of illness in patients with metastatic colorectal cancer. J Med Econ 2011; 14: 1-9.
    Open DOISearch in Google Scholar
  9. 9. Ferro SA, Myer BS, Wolff DA, Poniewierski MS, Culakova E, Cosler LE, et al. Variation in the cost of medications for the treatment of colorectal cancer. Am J Manag Care 2008; 14: 717-25.
    Search in Google Scholar
  10. 10. Paramore LC, Thomas SK, Knopf KB. Estimating costs of care for patients with newly diagnosed metastatic colorectal cancer. Clin Colorectal Cancer, 2006; 6: 52-8.
    Open DOISearch in Google Scholar
  11. 11. Bending WM, Trueman P, Lowson KV, Pilgrim H, Tappenden P, Chilcott J, et al. Estimating the direct costs of bowel cancer services provided by the National Health Service. Int J Technol Assess Health Care 2010; 26: 362-9.
    Open DOISearch in Google Scholar
  12. 12. Piškur P, Sonc M, Čufer T, Borštnar S, Mrhar A. Pharmacoeconomic aspects of adjuvant anastrozole or tamoxifen in breast cancer: A Slovenian perspective. Anticancer Drugs, 2006; 17: 719-24.
    Open DOISearch in Google Scholar
  13. 13. Obradovič M, Mrhar A, Kos M. Cost effectiveness of UGT1A1 genotypes in second line, high dose, once every three week irinotecan monotherapy treatment of colorectal cancer. Pharmacogenomics 2008; 9: 539-49.
    Open DOISearch in Google Scholar
  14. 14. Organisation for Economic Cooperation and Development. Health data. 2008, May. Available from: http://www.oecd-ilibrary.org/economics/country-statistical-profile-slovenia_20752288-table-svn. Accessed 10 August 2011.
    Search in Google Scholar
  15. 15. Marušič D, Ceglar J, Prevolnik-Rupel V. [Reimbursement of health care services with special attention paid to drg reimbursement system in Slovenia]. [Slovenian]. Zdrav Varst 2009; 48: 177-83.
    Search in Google Scholar
  16. 16. Busse R. Moving from passive to active provider payment systems: DRGbased financing. International conference markets in European health systems: opportunities, challenges and limitations; 2009. Available from: http://www.cef-see.org/health/#. Accessed 20 May 2009.
    Search in Google Scholar
  17. 17. Stariha J. [The adequacy of funding for acute hospital treatment after a system comparable groups of cases.] [Slovenian]. Master’s thesis. University of Primorska, Faculty of Management; 2009. Available at: http://www.ediplome.fm-kp.si/Stariha_Jurij_20091028.pdf. Accessed 10 August 2010.
    Search in Google Scholar
  18. 18. Zupanc I. [DRG: questions and answers about the classification system and the financing of hospitals.][Slovenian].Ljubljana: Inštitut za varovanje zdravja RS; 2008.
    Search in Google Scholar
  19. 19. Tekavčič M. [Cost management]. [Slovenian]. Ljubljana : Gospodarski vestnik, ISBN/ISSN: 867061149X; 1997.
    Search in Google Scholar
  20. 20. Grandlich C. Using activity-based costing in surgery. AORN J, 2004; 79: 18-192.
    Open DOISearch in Google Scholar
DOI: https://doi.org/10.2478/raon-2014-0046 | Journal eISSN: 1581-3207 | Journal ISSN: 1318-2099
Journal RSS Feed
Language: English
Page range: 200 - 208
Submitted on: Aug 14, 2014
Accepted on: Oct 2, 2014
Published on: Mar 25, 2015
Published by: Association of Radiology and Oncology
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year
Keywords:
cost of treatment,
metastatic colorectal cancer,
cost of targeted therapy,
monitoring costs
Related subjects:
Medicine,
Clinical medicine,
Radiology

© 2015 Tanja Mesti, Biljana Mileva Boshkoska, Mitja Kos, Metka Tekavčič, Janja Ocvirk, published by Association of Radiology and Oncology
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Volume 49 (2015): Issue 2 (June 2015)
Previous article